Abstract
Objectives: Patients’ oncological outcome after radical cystectomy (RC) due to urothelial carcinoma of the urinary bladder (UCB) is always up for debate. There is accumulating evidence on the influence of routine blood parameters. We aimed to identify reasonable and easy-to-detect biomarkers, such as preoperative C-reactive protein (CRP) and hemoglobin (Hb) levels, as predictors of overall survival (OS) and cancer-specific survival (CSS) in patients undergoing RC for UCB. Materials and Methods: This is a large single-center study in which both preoperative CRP and Hb levels were available in 1,043 patients undergoing RC for UCB from 2004 to 2018 with a median follow-up time of 22 months (mean 38, max. 170). We used the Kaplan-Meier method, log-rank test, and Cox regression models for assessment of OS and CSS. Using our data, we validated an existing outcome prediction score (TNR-C). Results: Median CRP level was 0.5 mg/dL (IQR 0.2–1.4), and median Hb level was 13.4 g/dL (IQR 11.9–14.7). We found that patients with CRP values above the median reached a significantly lower median survival than those with CRP values below the median (23 vs. 83 months, p < 0.001). The TNR-C score was successfully validated, and we discriminated between 3 risk groups (5-year CSS: 76, 40, and 16% for low, intermediate, and high risk, respectively). We observed a similar outcome for patients with a Hb level below the median: CSS was significantly poorer than with Hb levels above the median (median CSS 27 vs. 91 months, p < 0.001). Multivariant analysis showed CRP and Hb levels to be independent prognostic parameters for CSS and OS. Conclusions: We found elevated preoperative CRP levels and decreased Hb levels to be independent prognostic factors indicating an unfavorable outcome in patients undergoing RC for UCB and were able to validate the TNR-C score in a large patient cohort. We propose using these routine biomarkers for individual risk stratification and optimization of therapeutic strategies in patients undergoing RC for UCB.
References
1.
AmericanCancerSociety. Key Statistics for Bladder Cancer. https://wwwcancerorg/cancer/bladder-cancer/about/key-statisticshtml.
2018
.2.
Burger
M
, Catto
JW
, Dalbagni
G
, Grossman
HB
, Herr
H
, Karakiewicz
P
, et al. Epidemiology and risk factors of urothelial bladder cancer
. Eur Urol
. 2013
Feb
;63
(2
):234
–41
.
[PubMed]
0302-28383.
Smith
AB
, Deal
AM
, Woods
ME
, Wallen
EM
, Pruthi
RS
, Chen
RC
, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base
. BJU Int
. 2014
Nov
;114
(5
):719
–26
.
[PubMed]
1464-40964.
Charlton
ME
, Adamo
MP
, Sun
L
, Deorah
S
. Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010
. Cancer
. 2014
Dec
;120
Suppl 23
:3815
–25
.
[PubMed]
0008-543X5.
Karakiewicz
PI
, Shariat
SF
, Palapattu
GS
, Gilad
AE
, Lotan
Y
, Rogers
CG
, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder
. J Urol
. 2006
Oct
;176
(4 Pt 1
):1354
–61
.
[PubMed]
0022-53476.
Xylinas
E
, Rink
M
, Novara
G
, Green
DA
, Clozel
T
, Fritsche
HM
, et al. Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy
. Ann Surg Oncol
. 2013
Mar
;20
(3
):1027
–34
.
[PubMed]
1068-92657.
Guo
Y
, Cai
K
, Mao
S
, Zhang
J
, Wang
L
, Zhang
Z
, et al. Preoperative C-reactive protein/albumin ratio is a significant predictor of survival in bladder cancer patients after radical cystectomy: a retrospective study
. Cancer Manag Res
. 2018
Oct
;10
:4789
–804
.
[PubMed]
1179-13228.
Grimm
T
, Buchner
A
, Schneevoigt
B
, Kretschmer
A
, Apfelbeck
M
, Grabbert
M
, et al. Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study
. World J Urol
. 2016
May
;34
(5
):703
–8
.
[PubMed]
0724-49839.
Shrotriya
S
, Walsh
D
, Nowacki
AS
, Lorton
C
, Aktas
A
, Hullihen
B
, et al. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors
. PLoS One
. 2018
Aug
;13
(8
):e0202555
.
[PubMed]
1932-620310.
Morizane
S
, Iwamoto
H
, Masago
T
, Yao
A
, Isoyama
T
, Sejima
T
, et al. Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma
. Int Urol Nephrol
. 2013
Feb
;45
(1
):99
–106
.
[PubMed]
0301-162311.
Paitan
V
, Alcarraz
C
, Leonardo
A
, Valencia
G
, Mantilla
R
, Morante
Z
, et al. [Anemia as a prognostic factor in cancer patients]
. Rev Peru Med Exp Salud Publica
. 2018
Apr-Jun
;35
(2
):250
–8
.
[PubMed]
1726-463412.
Alfred Witjes
J
, Lebret
T
, Compérat
EM
, Cowan
NC
, De Santis
M
, Bruins
HM
, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
. Eur Urol
. 2017
Mar
;71
(3
):462
–75
.
[PubMed]
0302-283813.
Gakis
G
, Todenhöfer
T
, Renninger
M
, Schilling
D
, Sievert
KD
, Schwentner
C
, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score
. BJU Int
. 2011
Dec
;108
(11
):1800
–5
.
[PubMed]
1464-409614.
Kersten
C
, Louhimo
J
, Ålgars
A
, Lahdesmaki
A
, Cvancerova
M
, Stenstedt
K
, et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer
. Acta Oncol
. 2013
Nov
;52
(8
):1691
–8
.
[PubMed]
0284-186X15.
Xu
L
, Zhao
Q
, Huang
S
, Li
S
, Wang
J
, Li
Q
. Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients
. Tumour Biol
. 2015
Feb
;36
(2
):669
–73
.
[PubMed]
1010-428316.
Hrab
M
, Olek-Hrab
K
, Antczak
A
, Kwias
Z
, Milecki
T
. Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC)
. Rep Pract Oncol Radiother
. 2013
Jul
;18
(5
):304
–9
.
[PubMed]
1507-136717.
Fujita
K
, Uemura
M
, Yamamoto
Y
, Tanigawa
G
, Nakata
W
, Sato
M
, et al. Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy
. Int J Clin Oncol
. 2015
Feb
;20
(1
):156
–63
.
[PubMed]
1341-962518.
Allin
KH
, Bojesen
SE
, Nordestgaard
BG
. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer
. J Clin Oncol
. 2009
May
;27
(13
):2217
–24
.
[PubMed]
0732-183X19.
Balkwill
F
, Mantovani
A
. Inflammation and cancer: back to Virchow?
Lancet
. 2001
Feb
;357
(9255
):539
–45
.
[PubMed]
0140-673620.
Okamoto
M
, Hattori
K
, Oyasu
R
. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro
. Int J Cancer
. 1997
Jul
;72
(1
):149
–54
.
[PubMed]
0020-713621.
Aggarwal
BB
, Gehlot
P
. Inflammation and cancer: how friendly is the relationship for cancer patients?
Curr Opin Pharmacol
. 2009
Aug
;9
(4
):351
–69
.
[PubMed]
1471-489222.
DeNardo
DG
, Johansson
M
, Coussens
LM
. Immune cells as mediators of solid tumor metastasis
. Cancer Metastasis Rev
. 2008
Mar
;27
(1
):11
–8
.
[PubMed]
0167-765923.
Weis
SM
, Cheresh
DA
. Tumor angiogenesis: molecular pathways and therapeutic targets
. Nat Med
. 2011
Nov
;17
(11
):1359
–70
.
[PubMed]
1078-895624.
Huang
Y
, Wei
S
, Jiang
N
, Zhang
L
, Wang
S
, Cao
X
, et al. The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis
. BMC Cancer
. 2018
Dec
;18
(1
):1235
.
[PubMed]
1471-240725.
Schubert
T
, Todenhöfer
T
, Mischinger
J
, Schwentner
C
, Renninger
M
, Stenzl
A
, et al. The prognostic role of pre-cystectomy hemoglobin levels in patients with invasive bladder cancer
. World J Urol
. 2016
Jun
;34
(6
):829
–34
.
[PubMed]
0724-498326.
Joynson
CP
, Sundar
S
, Symonds
P
. Anaemia is associated with poor overall survival but not with inferior local control in patients with muscle invasive bladder carcinoma treated by radical external beam radiotherapy. A retrospective study
. Clin Oncol (R Coll Radiol)
. 2006
Dec
;18
(10
):728
–34
.
[PubMed]
0936-655527.
Yang
MH
, Wu
MZ
, Chiou
SH
, Chen
PM
, Chang
SY
, Liu
CJ
, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis
. Nat Cell Biol
. 2008
Mar
;10
(3
):295
–305
.
[PubMed]
1465-739228.
Xia
G
, Kumar
SR
, Hawes
D
, Cai
J
, Hassanieh
L
, Groshen
S
, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer
. J Urol
. 2006
Apr
;175
(4
):1245
–52
.
[PubMed]
0022-534729.
Morceau
F
, Dicato
M
, Diederich
M
. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis
. Mediators Inflamm
. 2009
;2009
:405016
.
[PubMed]
0962-935130.
Icardi
A
, Sacco
P
, Tarroni
A
, Cappelletti
L
, Cozzolino
M
. [Role of inflammation on renal anaemia]
. G Ital Nefrol
. 2013
Nov-Dec
;30
(6
):gin/30.6.13
.
[PubMed]
1724-599031.
Langdon
JM
, Yates
SC
, Femnou
LK
, McCranor
BJ
, Cheadle
C
, Xue
QL
, et al. Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation
. Am J Hematol
. 2014
May
;89
(5
):470
–9
.
[PubMed]
0361-8609© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
